These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 8792694)
1. Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. The Lansoprazole Maintenance Study Group. Sontag SJ; Kogut DG; Fleischmann R; Campbell DR; Richter J; Haber M Am J Gastroenterol; 1996 Sep; 91(9):1758-65. PubMed ID: 8792694 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group. Castell DO; Richter JE; Robinson M; Sontag SJ; Haber MM Am J Gastroenterol; 1996 Sep; 91(9):1749-57. PubMed ID: 8792693 [TBL] [Abstract][Full Text] [Related]
3. Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy. Sontag SJ; Kogut DG; Fleischmann R; Campbell DR; Richter J; Robinson M; McFarland M; Sabesin S; Lehman GA; Castell D Am J Gastroenterol; 1997 Mar; 92(3):429-37. PubMed ID: 9068463 [TBL] [Abstract][Full Text] [Related]
4. Daily low-dose versus alternate day full-dose lansoprazole in the maintenance treatment of reflux esophagitis. Baldi F; Morselli-Labate AM; Cappiello R; Ghersi S; Am J Gastroenterol; 2002 Jun; 97(6):1357-64. PubMed ID: 12094850 [TBL] [Abstract][Full Text] [Related]
5. Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+/K(+)-ATPase inhibitor: a controlled, double-blind study. Lansoprazole Study Group. Feldman M; Harford WV; Fisher RS; Sampliner RE; Murray SB; Greski-Rose PA; Jennings DE Am J Gastroenterol; 1993 Aug; 88(8):1212-7. PubMed ID: 8101695 [TBL] [Abstract][Full Text] [Related]
6. [Long-term maintenance treatment of reflux esophagitis resistant to H2-RA with PPI (lansoprazole)]. Endo M; Sugihara K Nihon Rinsho; 2000 Sep; 58(9):1865-70. PubMed ID: 11004817 [TBL] [Abstract][Full Text] [Related]
7. Comparison of once daily doses of lansoprazole (15, 30, and 60 mg) and placebo in patients with gastric ulcer. Avner DL; Movva R; Nelson KJ; McFarland M; Berry W; Erfling W Am J Gastroenterol; 1995 Aug; 90(8):1289-94. PubMed ID: 7639232 [TBL] [Abstract][Full Text] [Related]
8. A placebo-controlled dose-ranging study of lansoprazole in the management of reflux esophagitis. Earnest DL; Dorsch E; Jones J; Jennings DE; Greski-Rose PA Am J Gastroenterol; 1998 Feb; 93(2):238-43. PubMed ID: 9468251 [TBL] [Abstract][Full Text] [Related]
9. Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview. Chiba N Can J Gastroenterol; 1997 Sep; 11 Suppl B():66B-73B. PubMed ID: 9347181 [TBL] [Abstract][Full Text] [Related]
10. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis. Harris RA; Kuppermann M; Richter JE Am J Gastroenterol; 1997 Dec; 92(12):2179-87. PubMed ID: 9399748 [TBL] [Abstract][Full Text] [Related]
11. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Johnson DA; Benjamin SB; Vakil NB; Goldstein JL; Lamet M; Whipple J; Damico D; Hamelin B Am J Gastroenterol; 2001 Jan; 96(1):27-34. PubMed ID: 11197282 [TBL] [Abstract][Full Text] [Related]
13. [Reflux esophagitis: a comparative study of lansoprazole and omeprazole as short-term therapy. Preliminary report]. Córdova-Villalobos JA; Ramírez-Barba EJ; Ramírez-Covarrubias JC Rev Gastroenterol Mex; 1996; 61(4):306-9. PubMed ID: 9072780 [TBL] [Abstract][Full Text] [Related]
14. Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: short- and long-term treatment. The Dutch Reflux Study Group. Festen HP; Schenk E; Tan G; Snel P; Nelis F Am J Gastroenterol; 1999 Apr; 94(4):931-6. PubMed ID: 10201459 [TBL] [Abstract][Full Text] [Related]
15. [Cost-effectiveness of the treatment of reflux esophagitis: proton pump inhibitor versus histamine-2-receptor antagonist]. Habu Y; Oyasu K; Wakamatsu T; Sumitomo Y; Kiyota K; Inokuchi H; Kawai K Nihon Rinsho; 2000 Sep; 58(9):1881-5. PubMed ID: 11004820 [TBL] [Abstract][Full Text] [Related]
16. Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus. Sampliner RE Am J Gastroenterol; 1994 Oct; 89(10):1844-8. PubMed ID: 7942680 [TBL] [Abstract][Full Text] [Related]
17. Selection of patients for successful maintenance treatment of esophagitis with low-dose omeprazole: use of 24-hour gastric pH monitoring. Ladas SD; Tassios PS; Raptis SA Am J Gastroenterol; 2000 Feb; 95(2):374-80. PubMed ID: 10685738 [TBL] [Abstract][Full Text] [Related]
18. Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials. Peura DA; Kovacs TO; Metz DC; Siepman N; Pilmer BL; Talley NJ Am J Med; 2004 Jun; 116(11):740-8. PubMed ID: 15144910 [TBL] [Abstract][Full Text] [Related]
19. Lansoprazole: a comprehensive review. Zimmermann AE; Katona BG Pharmacotherapy; 1997; 17(2):308-26. PubMed ID: 9085323 [TBL] [Abstract][Full Text] [Related]
20. Treatment of gastroesophageal (acid) reflux with lansoprazole: an overview. Dobrilla G; Di Fede F Clin Ther; 1993; 15 Suppl B():2-13. PubMed ID: 7911400 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]